U.S. FDA Approves Japan Tobacco's Single-Dose Anti-HIV Drug
This article was originally published in PharmAsia News
Executive Summary
Japan Tobacco's JTK-303 single-dose anti-HIV drug won approval by the U.S. FDA as applied by Gilead Sciences, the U.S. company with global rights to develop and market the drug except in Japan.